A Double-Blind, Double-Dummy, Two-Way Cross-Over, Randomised, Phase II Study of Efficacy, Safety and Tolerability of Modified-Release Hydrocortisones: Chronocort® Versus Plenadren®, in Adrenal Insufficiency - Chronocort versus Plenadren replacement therapy in adults with adrenal insufficiency

Diurnal Limited0 个研究点目标入组 50 人开始时间: 2021年8月27日最近更新: 2024年1月8日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Diurnal Limited
入组人数: 50

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Male and female participants aged =18 years.
•2. Participants with known (documented) primary AI, defined as early morning pre-dose cortisol <50 nmol/L and currently treated with glucocorticoid as replacement therapy. Primary AI includes any cause of acquired or congenital primary adrenal failure including autoimmune Addison’s disease and bilateral adrenalectomy (except when performed for Cushing’s syndrome).
•3. Participants on stable glucocorticoid treatment for =3 months prior to the Screening Visit
•4. Participants on a stable dose of fludrocortisone (if applicable) for =3 months prior to the Screening Visit.
•5. Male participants must agree to use contraception as detailed in Appendix 4 during the Screening, Treatment, and Follow-up Periods and refrain from donating sperm during these periods and for 7 days after the last dose of study treatment.
•6. A female participant is eligible to participate if she is not pregnant, not breastfeeding, and for whom at least one of the following conditions applies: not a woman of childbearing potential (WOCBP) as defined in Appendix 4, or a WOCBP with a negative urine pregnancy test at entry into the study who agrees to follow the contraceptive guidance described in Appendix 4 during the Screening, Treatment and Follow-up Periods and for 7 days after the last dose of study treatment. Note: Females presenting with oligomenorrhea or amenorrhea who are =55 years should be considered potentially fertile (unless permanently sterile) and therefore, as well as undergoing pregnancy testing like all other female participants, will be expected to use an acceptable method of contraception as described in Appendix 4 during the Screening, Treatment and Follow-up Periods and for 7 days after the last dose of study treatment.
•7. Capable of giving signed informed consent (as described in Appendix 1), which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 28
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 22

排除标准

•1. Participants with CAH.
•2. Participants with secondary and tertiary AI.
•3. Past or current history of Cushing’s syndrome.
•4. Adrenal suppression and/or AI induced by exogenous steroids.
•5. Drug-induced AI.
•6. Clinical or biochemical evidence of hepatic disease: elevated liver function tests (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3 times the upper limit of normal [ULN]).
•7. Clinical or biochemical evidence of renal disease: serum creatinine level of >221 µmol/L (2.5 mg/dL) or calculated creatinine clearance of <25 mL/min.
•8. History of malignant brain tumours or traumatic brain injury.
•9. History of malignancy within the last 5 years or treated basal cell carcinoma within the past year.
•10. Participants who have type 1 diabetes or type 2 diabetes receiving regular insulin.
•11. Participants with type 2 diabetes whose screening HbA1c exceeds 9%.
•12. Participants who have elective surgical procedures scheduled during the study.
•13. Participants with significant medical or psychiatric conditions that in the opinion of the Investigator would preclude participation in the study.
•14. Participants who have had bariatric surgery within the past 6 months and participants who plan to undertake a major weight loss and/or exercise program during the same time period as anticipated study involvement.
•15. Restless legs syndrome/Willis-Ekbom disease.
•16. Participants who have increased gastrointestinal motility e.g., chronic diarrhoea, that may be at risk of impaired cortisol exposure. There are no data in patients with confirmed slow gastric emptying or decreased motility disease/disorder so the clinical response should be monitored in patients with these conditions.
•17. Participants anticipating regular prophylactic use of additional steroids e.g., for strenuous exercise.
•18. Participants with co-morbidities requiring daily administration of a medication (or consumption of any material) that interferes with the metabolism of glucocorticoids.
•19. Participants on regular daily inhaled, topical, nasal, or oral steroids for any indication other than AI.
•20. Participants who have received intra-articular steroid injections within 1 year prior to the Screening Visit or for whom such injections are planned during the study.
•21. Participants who are receiving <10 mg hydrocortisone dose at the Screening Visit or the hydrocortisone dose equivalent.
•22. Participants taking sleeping medication.
•23. Participants treated at screening with either Chronocort or Plenadren.
•24. Participation in another clinical study of an investigational or licensed drug or device within 12 weeks or 5 half-lives prior to the Screening Visit or at any time during study participation.
•25. Active alcohol or drug abuse within 1 year prior to the Screening Visit.
•26. Participants who routinely work night shifts and do not sleep during the usual night-time hours.
•27. Participants who intend to travel and cross a time zone of greater than ±3 hours within 1 week of the scheduled visit dates.
•28. Participants unable to comply with the requirements of the protocol in the opinion of the Investigator.
•29. Participants with a known hypersensitivity to any of the components of the Chronocort capsules, the Plenadren tablets, the Chronocort placebo, or the Plenadren placebo

研究者

发起方

Diurnal Limited

相似试验

进行中（未招募）

1 期

A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 14.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865

EUCTR2012-002215-26-ESAbbott Laboratories GmbH1,066

进行中（未招募）

1 期

A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 15.1Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865

EUCTR2012-002215-26-BEAbbott Laboratories GmbH1,066

进行中（未招募）

1 期

A study to compare if 30mg of oral Dydrogesterone is as good, tolerable and safe as 600mg of intravaginal capsules for luteal support in IVF pregnancies. This study will be conducted at several study sites and neither the patient or the doctor will know which of the two different treatments a patient will receive.Female infertilityMedDRA version: 19.0Level: LLTClassification code 10003540Term: Assisted fertilizationSystem Organ Class: 100000004865

EUCTR2012-002215-26-ATAbbott Laboratories GmbH1,066

进行中（未招募）

1 期

EUCTR2012-002215-26-FIAbbott Laboratories GmbH1,066

进行中（未招募）

不适用

A Randomised, Double-Blind, Double-Dummy Cross-Over Study to demonstrate Superiority of Fluticasone/ Salmeterol pMDI over double the dose of Fluticasone pMDI on Methacholine Hyper-Reactivity in Patients with Persistent, Mild to Moderate Asthma (as defined by GINA guidelines). - NEO 040/FPSM/pMDI/ChallengeSuperiorAsthma

EUCTR2008-001027-59-GBniversity of Dundee